Methods for treatment of muscular dystrophies

4-7. (canceled)

9-17. (canceled)

20-25. (canceled)

27-29. (canceled)

31-33. (canceled)

(canceled)

(canceled)

42-43. (canceled)

45-46. (canceled)

(canceled)

A pharmaceutical composition comprising Compound (I) or a pharmaceutically acceptable salt thereof, or comprising Compound (II) or a pharmaceutically acceptable salt thereof,

• wherein the pharmaceutical composition comprises about 0.1 mg to about 1 mg of the Compound (I) or pharmaceutically acceptable salt thereof, or comprises about 0.1 mg to about 1 mg of the Compound (II) or pharmaceutically acceptable salt thereof.

51-56. (canceled)

58-62. (canceled)

A method of treating muscular dystrophy in a subject, the method comprising:

• (a) determining whether a subject suffers from or is susceptible to muscular dystrophy;
• (b) selecting the subject for treatment based on the determining;
• (c) administering a therapeutically effective amount of Compound (I) or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of Compound (II) or a pharmaceutically acceptable salt thereof, thereby treating muscular dystrophy in the subject.

64-66. (canceled)